AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$LXRX

LEXICON PHARMACEUTICALS, INC.

Price · $LXRXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $LXRX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $LXRX in the last 30 days.

Top stories · $LXRXMore →
MAY 10·Insider MonkeyMed

Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones

Lexicon Pharmaceuticals Inc. reported a Q1 2026 revenue of $21.1 million, a substantial increase from $1.3 million year-over-year, largely due to a $20.0 million milestone payment from its Novo Nordisk partnership. The company significantly reduced its net loss to $1.0 million and strengthened its financial position with $199.7 million in cash and a new $100 million loan facility. Lexicon is also advancing its clinical pipeline with studies for sotagliflozin and pilavapadin, and plans to resubmit its NDA for ZYNQUISTA.

MAY 9·Insider Monkey

5 Best Fast Growing Penny Stocks to Buy Right Now

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is highlighted as a fast-growing penny stock due to its significant Q1 2026 revenue increase to $21.1 million, driven by a partnership with Novo Nordisk, and a sharp reduction in net loss. The company is advancing several clinical programs, including the Phase 3 SONATA-HCM study and NDA resubmission for ZYNQUISTA, while also preparing for Phase 3 development of pilavapadin for diabetic peripheral neuropathic pain. Lexicon's strengthened financial position with $199.7 million in cash and a new $100 million loan facility further supports its growth trajectory.

MAR 22·Intellectia AI

LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison

This article analyzes the financial performance of Lexicon Pharmaceuticals Inc (LXRX), focusing on its revenue breakdown, profitability margins, and competitive standing. It highlights LXRX's high gross margin but negative operating and net margins, indicating challenges in converting operational activities into shareholder value. The article also benchmarks LXRX against competitors like TBPH and EVO within the market.

News on $LXRX

All news →